PHILADELPHIA, Aug. 29, 2012 /PRNewswire/ -- Bioquark, Inc., (www.bioquark.com) a biopharmaceutical company engaged in the development of proprietary biological drugs that can be simultaneously leveraged for both the regeneration and repair of human organs and tissues, today announced that Ira S. Pastor, Chief Executive Officer, will present the Company's overview at the Rodman and Renshaw Annual Global Investment Conference's (14th Annual Healthcare Conference) on Tuesday, September 11, 2012, at 10:00 a.m. Eastern time at the Waldorf Astoria Hotel in New York City.
"The Rodman and Renshaw Conference is one of the year's most effective opportunities to present to investors and analysts," said Pastor. "As such, it represents a key step becoming a public company."
"Being represented by JSBarkats as our securities counsel, we benefit from both the experience and the network, not to mention the unprecedented value added strategy," added Mark Corrao, Bioquark's Chief Financial Officer.
About Bioquark, Inc.
Bioquark, Inc. is developing proprietary biologics that can be simultaneously applied for both regeneration and repair of human organs and tissues. To date, Bioquark has demonstrated direct microenvironment remodeling of diseased, damaged, and aged tissues in mammals, utilizing its lead development candidate, BQ-A. With global healthcare costs now surpassing $6 trillion annually, and the majority being spent on diseases with underlying cellular degeneration or damage component, BQ-A represents a lucrative and transformational therapeutic opportunity.
About Rodman & Renshaw, LLC
Rodman & Renshaw Capital Group, Inc. is a holding company with a number of direct and indirect subsidiaries, including Rodman & Renshaw, LLC. Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and relat
|SOURCE Bioquark Inc.|
Copyright©2012 PR Newswire.
All rights reserved